股本结构
单位：万股
| 公告日期 | 2025-11-18 | 2025-11-18 | 2025-10-14 | 2025-09-25 | 2025-09-22 | 2025-08-14 |
|---|---|---|---|---|---|---|
| 证券总股本 | 4130.14 | 4029.92 | 4029.92 | 4029.56 | 3938.23 | 107.73 |
| 普通股本 | 4130.14 | 4029.92 | 4029.92 | 4029.56 | 3938.23 | 107.73 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-17 | 2025-09-30 | 2025-09-26 | 2025-09-24 | 2025-09-18 | 2025-08-08 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-18 | 4130.14 | 未披露 | 定期报告 | 2025-11-17 |
| 2025-11-18 | 4029.92 | 未披露 |
更多>>
From July 1,2025 to September 30,2025
Issuance of common stock in at-the-market public offering
Issuance of common stock and common stock warrants in private placement
Exercise of warrants
|
2025-09-30 |
| 2025-10-14 | 4029.92 | 未披露 | 定期报告 | 2025-09-26 |
| 2025-09-25 | 4029.56 | 未披露 | 定期报告 | 2025-09-24 |
| 2025-09-22 | 3938.23 | 未披露 | 定期报告 | 2025-09-18 |
| 2025-08-14 | 107.73 | 未披露 | 定期报告 | 2025-08-08 |
| 2025-06-27 | 70.00 | 未披露 |
更多>>
a 1-for-50 reverse split of its Class A common stock
|
2025-07-01 |
| 2025-06-27 | 3380.00 | 未披露 | 定期报告 | 2025-06-27 |
| 2025-06-23 | 3491.31 | 未披露 | 定期报告 | 2025-06-17 |
| 2025-06-10 | 315.51 | 未披露 | 定期报告 | 2025-06-05 |
| 2025-04-30 | 50.00 | 未披露 |
更多>>
a 1-for-15 reverse split of its Class A common stock
|
2025-05-02 |
| 2025-04-30 | 790.00 | 未披露 | 定期报告 | 2025-04-30 |
| 2025-05-01 | 792.09 | 未披露 | 定期报告 | 2025-04-28 |
| 2025-05-01 | 612.68 | 未披露 |
更多>>
From January 1, 2025 to March 31, 2025
Issuance of common stock in public offering
Exercise of warrants, net of issuance costs
|
2025-03-31 |
| 2025-03-26 | 608.58 | 未披露 | 定期报告 | 2025-03-26 |
| 2025-03-25 | 612.68 | 未披露 | 定期报告 | 2025-03-12 |
| 2025-01-31 | 567.42 | 未披露 | 定期报告 | 2025-01-24 |
| 2024-11-12 | 372.82 | 未披露 | 定期报告 | 2024-11-07 |
| 2024-11-12 | 364.61 | 未披露 |
更多>>
From July 1, 2024 to September 30, 2024
Exercise of warrants
|
2024-09-30 |
| 2024-08-12 | 357.62 | 未披露 | 定期报告 | 2024-08-07 |
| 2024-08-12 | 319.82 | 未披露 |
更多>>
From April 1, 2024 to June 30, 2024
Issuance of common stock in public offering
Exercise of warrants
Settlement of restricted stock units
|
2024-06-30 |
| 2024-05-31 | 296.32 | 未披露 | 定期报告 | 2024-05-28 |
| 2024-05-13 | 252.99 | 未披露 | 定期报告 | 2024-05-09 |
| 2024-05-08 | 88.84 | 未披露 | 定期报告 | 2024-05-06 |
| 2024-05-13 | 88.78 | 未披露 |
更多>>
From January 1, 2024 to March 31, 2024
Exercise of warrants
Settlement of restricted stock units
Issuance of common stock in public offering
|
2024-03-31 |
| 2024-03-28 | 88.73 | 未披露 | 定期报告 | 2024-03-01 |
| 2024-03-28 | 71.46 | 未披露 |
更多>>
From January 1, 2023 to December 31, 2023
Issuance of common stock in public offering
Exercise of warrants
Settlement of restricted stock units
|
2023-12-31 |
| 2023-11-09 | 70.82 | 未披露 | 定期报告 | 2023-11-03 |
| 2023-11-09 | 68.78 | 未披露 |
更多>>
From July 1, 2023 to September 30, 2023
Exercise of warrants
Settlement of restricted stock units
Issuance of common stock in public offering
|
2023-09-30 |
| 2023-08-16 | 57.00 | 未披露 |
更多>>
Helius Medical Technologies, Inc. announced a 1-for-50 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on August 16, 2023.
|
2023-08-17 |
| 2023-08-10 | 2829.84 | 未披露 | 定期报告 | 2023-08-03 |
| 2023-08-10 | 2827.08 | 未披露 |
更多>>
From April 1, 2023 to June 30, 2023
Settlement of restricted stock units
|
2023-06-30 |
| 2023-05-11 | 2821.54 | 未披露 | 定期报告 | 2023-05-03 |
| 2023-04-21 | 2821.34 | 2.82 | 定期报告 | 2023-04-05 |
| 2023-05-25 | 2821.34 | 未披露 | 定期报告 | 2023-03-31 |
| 2023-03-09 | 2821.14 | 未披露 | 定期报告 | 2023-03-06 |
| 2023-03-09 | 2820.73 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Settlement of restricted stock units
Common stock issued for services
Stock-based compensation
Issuance of common stock in public offering
Common stock issued under equity line of credit
|
2022-12-31 |
| 2022-11-14 | 2820.33 | 未披露 | 定期报告 | 2022-11-11 |
| 2022-11-14 | 2820.13 | 未披露 |
更多>>
From July 1, 2022 to September 30, 2022
Issuance of common stock in public offering
Settlement of restricted stock units
|
2022-09-30 |
| 2022-08-15 | 2819.72 | 未披露 | 定期报告 | 2022-08-09 |
| 2022-08-15 | 419.51 | 未披露 |
更多>>
From April 1, 2022 to June 30, 2022
Common stock issued under equity line of credit
Common stock issued for services
Settlement of restricted stock units
|
2022-06-30 |
| 2022-05-12 | 379.76 | 未披露 | 定期报告 | 2022-05-04 |
| 2022-04-22 | 379.67 | 未披露 | 定期报告 | 2022-04-04 |
| 2022-05-12 | 379.48 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Settlement of restricted stock units
Issuance of shares to a consultant for services
Stock-based compensation
|
2022-03-31 |
| 2022-03-14 | 379.43 | 未披露 | 定期报告 | 2022-03-04 |
| 2022-03-14 | 378.07 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Proceeds from the issuance of common stock from the February 2021 Offering
Proceeds from issuance of common stock pursuant to the LPC Purchase Agreement
Proceeds from issuance of common stock from the November 2021 Offering
Share issuance costs
Proceeds from the exercise of warrants
Proceeds from the exercise of stock options
Settlement of restricted stock units
Issuance of shares to a consultant for services
Stock-based compensation
|
2021-12-31 |
| 2021-11-12 | 359.65 | 未披露 |
更多>>
1.Common stock offered 1,204,375 shares.
2.The number of shares of common stock that will be outstanding after this offering as shown above is based on 2,392,130 shares of common stock outstanding as of September 30, 2021.
|
2021-11-12 |
| 2021-11-09 | 239.36 | 未披露 | 定期报告 | 2021-11-04 |
| 2021-11-09 | 239.21 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Proceeds from the issuance of common stock pursuant to the LPC Purchase Agreement
Share issuance costs
Settlement of restricted stock units
|
2021-09-30 |
| 2021-08-12 | 231.78 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Proceeds from the exercise of warrants
Proceeds from the exercise of stock options
Settlement of restricted stock units
Issuance of shares as part of compensation
|
2021-06-30 |
| 2021-05-17 | 231.74 | 未披露 | 定期报告 | 2021-05-10 |
| 2021-04-23 | 231.73 | 未披露 | 定期报告 | 2021-04-08 |
| 2021-05-17 | 231.19 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Proceeds from the issuance of common stock from the February 2021 Offering
Proceeds from the exercise of warrants
Settlement of restricted stock units
|
2021-03-31 |
| 2021-03-10 | 231.11 | 未披露 | 定期报告 | 2021-03-05 |
| 2021-02-01 | 221.39 | 未披露 |
更多>>
1.The company is offering 647,772 Units. Each Unit consists of one share of common stock.
2.Except as otherwise indicated, all information in this prospectus is based on 1,566,163 shares of common stock outstanding as of January 11, 2021.
|
2021-02-01 |
| 2021-01-20 | 156.62 | 未披露 | 定期报告 | 2021-01-11 |
| 2020-12-31 | 150.00 | 未披露 |
更多>>
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today a 1-for-35 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time today. Beginning on January 4, 2021, the Company’s common stock will trade on The Nasdaq Capital Market and the Toronto Stock Exchange on a split adjusted basis. The number of authorized shares of the Company’s common stock will remain at 150 million, while the number of outstanding shares will be reduced from approximately 51.9 million to approximately 1.5 million.
|
2021-01-04 |
| 2020-12-30 | 5195.63 | 未披露 | 定期报告 | 2020-12-23 |
| 2020-11-25 | 5192.25 | 未披露 | 定期报告 | 2020-10-31 |
| 2020-11-12 | 4535.46 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Settlement of restricted stock units
|
2020-09-30 |
| 2020-08-12 | 4511.45 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Proceeds from the issuance of common stock from At-the-Market program
|
2020-06-30 |
| 2020-05-11 | 3804.17 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Proceeds from the issuance of common stock from At-the-Market program
Proceeds from issuance of common stock from the March 2020 Offering
|
2020-03-31 |
| 2020-03-12 | 3178.45 | 未披露 | 定期报告 | 2020-03-09 |
| 2020-03-12 | 3071.86 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Proceeds from the issuance of common stock from November 2019 Offering
Proceeds from exercise of stock options and warrants
Settlement of vested restricted stock units, net of taxes
|
2019-12-31 |
| 2019-11-26 | 3071.86 | 未披露 | 定期报告 | 2019-11-26 |
| 2019-08-08 | 2590.35 | 未披露 |
更多>>
from March 31, 2019 to June 30,2019
Proceeds from exercise of stock options and warrants
Settlement of restricted stock units
|
2019-06-30 |
| 2019-04-26 | 2586.62 | 未披露 | 定期报告 | 2019-04-25 |
| 2019-04-26 | 2585.84 | 未披露 | 定期报告 | 2019-04-15 |
| 2019-05-09 | 2584.42 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Proceeds from the exercise of warrants
|
2019-03-31 |
| 2019-03-14 | 2583.42 | 未披露 | 定期报告 | 2019-03-12 |
| 2019-03-14 | 2582.79 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Reclassification upon change in corporate domicile
Proceeds from issuance of common stock in connection with November 2018 public offering
Proceeds from exercise of stock options
|
2018-12-31 |
| 2018-11-08 | 2338.32 | 未披露 | 定期报告 | 2018-11-06 |
| 2018-11-08 | 2337.82 | 未披露 |
更多>>
from December 31, 2017 to September 30, 2018
Reclassification upon change in corporate domicile
Proceeds from the issuance of common stock and accompanying warrants from April 2018 public offering
Proceeds from the exercise of stock options and warrants
Settlement of vested restricted stock units, net of taxes
|
2018-09-30 |
| 2018-08-09 | 2337.75 | 未披露 | 定期报告 | 2018-08-07 |
| 2018-08-09 | 2337.75 | 未披露 |
更多>>
from December 31, 2017 to June 30, 2018
Proceeds from the exercise of stock options and warrants
Proceeds from the issuance of common stock and accompanying warrants from April 2018 public offering
|
2018-06-30 |
| 2018-05-29 | 2331.23 | 未披露 | 定期报告 | 2018-05-18 |
| 2018-05-29 | 2330.83 | 未披露 | 定期报告 | 2018-05-15 |
| 2018-04-30 | 2326.05 | 未披露 | 定期报告 | 2018-04-26 |
| 2018-04-11 | 2293.86 | 未披露 | 定期报告 | 2018-04-11 |
| 2018-05-08 | 2079.73 | 未披露 |
更多>>
from December 31, 2017 to March 31, 2018
Proceeds from the exercise of stock options and warrants
|
2018-03-31 |
From July 1,2025 to September 30,2025
Issuance of common stock in at-the-market public offering
Issuance of common stock and common stock warrants in private placement
Exercise of warrants
a 1-for-50 reverse split of its Class A common stock
a 1-for-15 reverse split of its Class A common stock
From January 1, 2025 to March 31, 2025
Issuance of common stock in public offering
Exercise of warrants, net of issuance costs
From July 1, 2024 to September 30, 2024
Exercise of warrants
From April 1, 2024 to June 30, 2024
Issuance of common stock in public offering
Exercise of warrants
Settlement of restricted stock units
From January 1, 2024 to March 31, 2024
Exercise of warrants
Settlement of restricted stock units
Issuance of common stock in public offering
From January 1, 2023 to December 31, 2023
Issuance of common stock in public offering
Exercise of warrants
Settlement of restricted stock units
From July 1, 2023 to September 30, 2023
Exercise of warrants
Settlement of restricted stock units
Issuance of common stock in public offering
Helius Medical Technologies, Inc. announced a 1-for-50 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on August 16, 2023.
From April 1, 2023 to June 30, 2023
Settlement of restricted stock units
From December 31, 2021 to December 31, 2022
Settlement of restricted stock units
Common stock issued for services
Stock-based compensation
Issuance of common stock in public offering
Common stock issued under equity line of credit
From July 1, 2022 to September 30, 2022
Issuance of common stock in public offering
Settlement of restricted stock units
From April 1, 2022 to June 30, 2022
Common stock issued under equity line of credit
Common stock issued for services
Settlement of restricted stock units
From December 31, 2021 to March 31, 2022
Settlement of restricted stock units
Issuance of shares to a consultant for services
Stock-based compensation
From December 31, 2020 to December 31, 2021
Proceeds from the issuance of common stock from the February 2021 Offering
Proceeds from issuance of common stock pursuant to the LPC Purchase Agreement
Proceeds from issuance of common stock from the November 2021 Offering
Share issuance costs
Proceeds from the exercise of warrants
Proceeds from the exercise of stock options
Settlement of restricted stock units
Issuance of shares to a consultant for services
Stock-based compensation
1.Common stock offered 1,204,375 shares.
2.The number of shares of common stock that will be outstanding after this offering as shown above is based on 2,392,130 shares of common stock outstanding as of September 30, 2021.
From June 30, 2021 to September 30, 2021
Proceeds from the issuance of common stock pursuant to the LPC Purchase Agreement
Share issuance costs
Settlement of restricted stock units
From March 31, 2021 to June 30, 2021
Proceeds from the exercise of warrants
Proceeds from the exercise of stock options
Settlement of restricted stock units
Issuance of shares as part of compensation
From December 31, 2020 to March 31, 2021
Proceeds from the issuance of common stock from the February 2021 Offering
Proceeds from the exercise of warrants
Settlement of restricted stock units
1.The company is offering 647,772 Units. Each Unit consists of one share of common stock.
2.Except as otherwise indicated, all information in this prospectus is based on 1,566,163 shares of common stock outstanding as of January 11, 2021.
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today a 1-for-35 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time today. Beginning on January 4, 2021, the Company’s common stock will trade on The Nasdaq Capital Market and the Toronto Stock Exchange on a split adjusted basis. The number of authorized shares of the Company’s common stock will remain at 150 million, while the number of outstanding shares will be reduced from approximately 51.9 million to approximately 1.5 million.
From June 30, 2020 to September 30, 2020
Settlement of restricted stock units
From March 31, 2020 to June 30, 2020
Proceeds from the issuance of common stock from At-the-Market program
From December 31, 2019 to March 31, 2020
Proceeds from the issuance of common stock from At-the-Market program
Proceeds from issuance of common stock from the March 2020 Offering
from December 31, 2018 to December 31, 2019
Proceeds from the issuance of common stock from November 2019 Offering
Proceeds from exercise of stock options and warrants
Settlement of vested restricted stock units, net of taxes
from March 31, 2019 to June 30,2019
Proceeds from exercise of stock options and warrants
Settlement of restricted stock units
from December 31, 2018 to March 31, 2019
Proceeds from the exercise of warrants
from December 31, 2017 to December 31, 2018
Reclassification upon change in corporate domicile
Proceeds from issuance of common stock in connection with November 2018 public offering
Proceeds from exercise of stock options
from December 31, 2017 to September 30, 2018
Reclassification upon change in corporate domicile
Proceeds from the issuance of common stock and accompanying warrants from April 2018 public offering
Proceeds from the exercise of stock options and warrants
Settlement of vested restricted stock units, net of taxes
from December 31, 2017 to June 30, 2018
Proceeds from the exercise of stock options and warrants
Proceeds from the issuance of common stock and accompanying warrants from April 2018 public offering
from December 31, 2017 to March 31, 2018
Proceeds from the exercise of stock options and warrants